SACUBITRIL / VALSARTAN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: COMPARATIVE PROFILE OF NT-PROBNP AND BNP

被引：0
|
作者：
Ajello, L. [1 ]
Romano, G. [1 ]
Agnese, V. [1 ]
Bellavia, D. [1 ]
Di Gesaro, G. [1 ]
Falletta, C. [1 ]
La Franca, E. [1 ]
Mina, C. [1 ]
Storniolo, S. [1 ]
Clemenza, F. [1 ]
机构：
[1] ISMETT, Palermo, Italy
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2019年 / 21卷 / 0E期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P251
引用
收藏
页码：E223 / E224
页数：2
相关论文
共 50 条
  • [41] NT-proBNP predicts cardiovascular outcomes in patients with heart failure and preserved ejection fraction
    Grewal, J.
    Lonn, E.
    Tait, P.
    Carlson, J.
    McKelvie, R.
    Persson, H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2007, 6 : 40 - 40
  • [42] Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
    Mohebi, Reza
    Liu, Yuxi
    Felker, G. Michael
    Prescott, Margaret F.
    Ward, Jonathan H.
    Pina, Ileana L.
    Butler, Javed
    Solomon, Scott D.
    Januzzi, James L.
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (12) : 1673 - 1682
  • [43] Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
    Rex C. Liu
    American Journal of Cardiovascular Drugs, 2018, 18 : 473 - 482
  • [44] Economic evaluation of sacubitril/valsartan for the treatment of heart failure with reduced ejection fraction
    Stafylas, P.
    Farmakis, D.
    Giamouzis, G.
    Hatzikou, M.
    Kourlaba, G.
    Papatsouma, I.
    Maniadakis, N.
    EUROPEAN HEART JOURNAL, 2016, 37 : 730 - 731
  • [45] Left ventricular ejection fraction recovery in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
    Diez Villanueva, P.
    De la Cuerda, F.
    Vicent, L.
    Esteban-Fernandez, A.
    Gomez-Bueno, M.
    De Juan, J.
    Iniesta, A. M.
    Ayesta, A.
    Rojas, A.
    Bover, R.
    Iglesias, D.
    Garcia Aguado, M.
    Perea Egido, J. A.
    Salamanca, J.
    Martinez-Selles, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 206 - 207
  • [46] Sacubitril/Valsartan in the primary treatment of heart failure with reduced ejection fraction (HFrEF)
    Nowak, Bernd
    Geiss, Ernst
    Boehm, Michael
    Weil, Joachim
    Boer, Jana
    KARDIOLOGIE, 2023, : 44 - 48
  • [47] Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction
    Raschi, Emanuel
    Diemberger, Igor
    Sabatino, Mario
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    Potena, Luciano
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (03) : 303 - 320
  • [48] Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
    Khan, Muhammad Nauman
    Soomro, Najia Aslam
    Naseeb, Khalid
    Bhatti, Usman Hanif
    Rauf, Rubina
    Balouch, Iram Jehan
    Moazzam, Ali
    Bashir, Sonia
    Ashraf, Tariq
    Karim, Musa
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [49] Sacubitril/valsartan reduces ventrucular arrhythmias in heart failure with reduced ejection fraction
    Lamaida, Norman
    Torella, Giorgio
    Cerciello, Antonio
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N26 - N26
  • [50] Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    Abumayyaleh, Mohammad
    El-Battrawy, Ibrahim
    Behnes, Michael
    Borggrefe, Martin
    Akin, Ibrahim
    FUTURE CARDIOLOGY, 2020, 16 (04) : 227 - 236
12345